/
FATE
$2.42+$0.32 (+15.24%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$244.8M
117M shares
52-week range
$0.91 – $2.88
77% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.94%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-91.87
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Cost of revenue | $56.0M | $0 | $125.6M | $5.8M | $13.8M | $157.2M | $118.5M | $12.9M |
| Gross profit | −$51.3M | $10.7M | −$94.2M | $50.0M | $82.5M | −$93.7M | −$104.9M | −$6.3M |
| Gross margin | -1081.9% | 100.0% | -299.6% | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| R&D | $56.0M | $87.8M | $125.6M | $215.5M | $320.5M | $172.6M | $135.0M | $107.8M |
| Operating income | −$67.1M | −$100.7M | −$128.1M | −$217.0M | −$308.4M | −$190.5M | −$210.3M | −$147.7M |
| EBITDA | −$63.7M | −$94.2M | −$125.0M | −$206.3M | −$268.0M | −$142.6M | −$176.6M | −$127.0M |
| Net income | −$66.6M | −$98.1M | −$173.4M | −$212.2M | −$281.7M | −$160.9M | −$186.3M | −$136.3M |
| Net margin | -1405.0% | -919.0% | -551.6% | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (diluted) | -1.19 | -1.43 | -2.10 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-1.08 | $-1.26–$-0.64 | 8 |
| 2027 | $5M | $-1.03 | $-1.46–$-0.34 | 7 |
| 2028 | $5M | $-1.07 | $-1.63–$-0.60 | 5 |
| 2029 | $60M | $-0.99 | $-2.54–$-0.21 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Fate Therapeutics, Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
www.fatetherapeutics.com- Employees
- 161
- IPO / List date
- Oct 1, 2013
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds FATE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,974,683 | $3.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FATE yet.
